| PP160317014014 |
MoonLake Immunotherapeutics AG |
ALX-0761, M1095 |
sonelokimab |
An anti- i.. |
Hidradenit.. |
Phase III completed, Phase II completed, Phase II, Phase III, Phase II |
View Details
|
| PP180502016464 |
Alnylam Pharmaceuticals, Inc. |
ALN-CC5 |
cemdisiran |
Targeting .. |
Myasthenia.. |
NDA, Phase III, Phase III |
View Details
|
| PP191015017593 |
Sanofi, Genzyme Corporation (a Sanofi company) |
Cenrifki, SAR442168, PRN2246 |
tolebrutinib |
A Bruton's.. |
Secondary .. |
Approved, Phase III, Phase III |
View Details
|
| PP200806018261 |
Amgen Inc. (since Oct 2023), Horizon Therapeutics plc |
Tepezza SC, HZN-001 |
teprotumumab |
An insulin.. |
Fibrotic t.. |
Phase III |
View Details
|
| PP210706018782 |
Viridian Therapeutics, Inc. |
Lumvoa, Veli, VRDN-001 IV, AVE-1642 |
veligrotug-vvze |
An anti-IG.. |
Thyroid ey.. |
Approved |
View Details
|
| PP230809021049 |
Viridian Therapeutics, Inc. |
Veli, VRDN-001 SC, AVE-1642 |
veligrotug |
An anti-IG.. |
Thyroid ey.. |
Phase III |
View Details
|
| PP260624024333 |
CureGene Pharmaceutical Co., Ltd. |
CG-0255 Oral |
evategrel |
The world’.. |
Acute coro.. |
Phase III |
View Details
|
| PP260624024334 |
CureGene Pharmaceutical Co., Ltd. |
CG-0255 IV |
evategrel |
The world’.. |
Adjunct to.. |
Phase III |
View Details
|
| PP260629024335 |
Steminent Therapeutics, Inc. |
Stemchymal |
|
|
Polyglutam.. |
NDA |
View Details
|
| PP260630024336 |
Elixirgen Therapeutics, Inc. |
EXG-7001 |
|
|
Duchenne m.. |
Preclinical completed |
View Details
|